By Delilah Alvarado | October 12, 2026
In a significant development for the millions of people living with celiac disease, First Tracks has unveiled promising early-stage clinical trial data for its investigational therapy, ANB033. The positive results, which demonstrate both efficacy in mitigating biological markers of the condition and a strong safety profile, have sparked investor optimism and renewed interest in the competitive race to develop the first-ever pharmacological treatment for the disorder.
The data, released on Monday, suggests that ANB033—a drug designed to block the CD122 receptor—could provide a critical secondary layer of protection for patients who remain symptomatic despite adhering to a strictly gluten-free diet. Following the announcement, First Tracks saw its shares climb approximately 7% in intraday trading, reflecting market confidence in the company’s broader "pipeline-in-a-product" strategy.
The Landscape of Celiac Disease: A Major Unmet Need
Celiac disease is a chronic autoimmune disorder characterized by a pathological immune response to gluten, a protein found in wheat, barley, and rye. When a person with celiac disease ingests gluten, their immune system mounts an attack on the small intestine, leading to the destruction of the villi—the tiny, finger-like projections that line the intestinal wall and facilitate nutrient absorption.
Over time, this damage can lead to severe health consequences, including malabsorption, chronic digestive distress, anemia, osteoporosis, and an increased risk of certain cancers. Currently, the only effective management strategy is a lifelong, strictly gluten-free diet. However, for many patients, the diet is difficult to maintain and does not always resolve inflammation or systemic symptoms, leaving a massive void in the therapeutic landscape.
"Celiac disease is the largest autoimmune disease without an approved treatment," noted Monique da Silva, senior vice president of corporate affairs at First Tracks. The pursuit of a "disease-modifying" therapy has become a "holy grail" for biotech firms, as the potential patient population is vast and currently underserved by the medical establishment.
Chronology of a Competitive Race
The race to treat celiac disease has intensified over the last several years, with several pharmaceutical giants and innovative biotechs vying for dominance.
- Early Research Phase: For years, researchers focused on enzymes and probiotics, but focus has shifted toward immunology-based interventions that target the underlying drivers of the disease: IL-2 and IL-15, two cytokines that regulate immune function and are heavily implicated in the inflammatory cascade triggered by gluten.
- The Rise of Competitors: Argenx and Teva Pharmaceuticals have emerged as the primary rivals to First Tracks in this space. Argenx, through a recent strategic acquisition, secured a therapy that, like ANB033, targets the CD122 receptor component. Meanwhile, Teva has been advancing a candidate that specifically hones in on the IL-15 pathway.
- The September 2026 Milestone: Last month, Teva Pharmaceuticals disclosed its own set of early clinical data, which set a high bar for the industry. The anticipation surrounding First Tracks’ Monday announcement was largely driven by the need to see how ANB033 would measure up against the Teva candidate.
- The October 2026 Data Drop: On October 12, 2026, First Tracks officially released its Phase 1 results, confirming that its subcutaneous administration method was both safe and biologically active in a controlled gluten-challenge study.
Supporting Data: The Anatomy of the ANB033 Trial
The First Tracks study was designed to rigorously test the drug’s ability to "dampen" the immune system’s reaction to a direct gluten challenge. The study enrolled 32 participants, all of whom were patients with confirmed celiac disease.
Methodology
Participants were randomized into two groups: one received a placebo, while the other received three subcutaneous doses of ANB033 over a four-week period. Following the treatment window, all participants underwent a two-week "gluten challenge," wherein they consumed the equivalent of two slices of bread per day—a dose typically sufficient to trigger significant intestinal inflammation and symptomatic distress in a celiac patient.
Key Findings
ANB033 hit statistical significance across three primary measures assessing biological signs of celiac disease. These markers, which indicate the degree of intestinal immune activation, were significantly suppressed in the ANB033 cohort compared to the placebo group. Perhaps most importantly for the future of the drug’s regulatory pathway, the company reported a "clean safety profile," with no serious adverse events reported among the study cohort.
Leerink Partners analyst David Risinger, in a client note issued shortly after the release, described the results as "impressive." While noting that no head-to-head clinical trials have been conducted, Risinger highlighted that the ANB033 data compares "favorably" to the results previously disclosed by Teva, suggesting that First Tracks may have a superior candidate in terms of efficacy or safety margin.
Official Responses and Strategic Implications
The market reaction was immediate and positive, reflecting the view that First Tracks is not merely developing a celiac drug, but a platform technology.
"We view ANB033 as having pipeline-in-a-product potential across several autoimmune diseases," Risinger wrote. This sentiment is supported by the company’s aggressive development roadmap. First Tracks is already leveraging the same underlying science to explore other indications where immune dysregulation is a common denominator.
Expanding the Pipeline
The company’s clinical strategy is multi-pronged:
- Eosinophilic Esophagitis (EoE): First Tracks is currently conducting a Phase 1b trial in patients with EoE, an inflammatory condition of the esophagus. Data from this trial is expected in the third quarter of 2027.
- Vitiligo: The company is on track to initiate Phase 2 development for vitiligo, a skin disorder characterized by the loss of pigment, in the first half of 2027.
- Unnamed Indications: First Tracks hinted at an additional, as-yet-unnamed autoimmune indication slated for Phase 2 entry in 2027, further diversifying its portfolio and reducing reliance on the success of a single program.
"Should the early results be confirmed in further testing," da Silva stated, "the drug could offer people with the condition a new layer of protection beyond the gluten-free diet." This "layer of protection" could eventually allow patients to tolerate accidental gluten exposure—a common occurrence—without the debilitating aftermath, effectively reclaiming a sense of normalcy in their daily lives.
The Path Forward: Challenges and Opportunities
While the early-stage data is undeniably encouraging, the path to commercialization remains fraught with challenges. The FDA and other global regulatory bodies require robust, large-scale, long-term Phase 2 and Phase 3 trials to ensure that a drug targeting the immune system does not cause long-term side effects, such as an increased susceptibility to infections or long-term immune suppression.
Furthermore, the "gluten challenge" methodology, while standard for Phase 1 trials, is notoriously difficult to translate into real-world, long-term efficacy outcomes. Future trials will need to demonstrate not just the suppression of biological markers, but an actual, measurable improvement in the quality of life for patients and a reduction in long-term intestinal damage.
As First Tracks prepares for its next phase of development, the biotech industry will be watching closely. The success of ANB033 could validate the CD122 pathway as a master key for treating a wide array of autoimmune diseases. If the company continues to hit its milestones through 2027, it may find itself as a primary acquisition target or a new leader in the lucrative autoimmune therapeutic space.
For the patient community, the news offers a rare glimmer of hope: the prospect that, in the not-too-distant future, the rigid dietary restrictions that define the celiac experience could be softened by a small, subcutaneous injection, fundamentally changing what it means to live with the disease.
About the Author
